[1] |
杨永生, 徐金华, 李锋, 等. 静脉注射丙种球蛋白和糖皮质激素治疗重症大疱性药疹65例[J]. 中华皮肤科杂志, 2009,42(5):330⁃332. doi: 10.3760/cma.j.issn.0412⁃4030.2009.05.012.
|
[2] |
孙杰, 刘晋, 龚晴丽, 等. 糖皮质激素和免疫球蛋白治疗中毒性表皮坏死松解症疗效分析[J]. 中华皮肤科杂志, 2015,48(9):633⁃636. doi: 10.3760/cma.j.issn.0412⁃4030.2015.09.010.
|
[3] |
陈蕾, 李定, 马萍萍, 等. 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合糖皮质激素治疗中毒性表皮坏死松解症一例[J]. 中华皮肤科杂志, 2021,54(4):356⁃357. doi: 10.35541/cjd.20190896.
|
[4] |
Bastuji⁃Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity⁃of⁃illness score for toxic epidermal necrolysis[J]. J Invest Dermatol, 2000,115(2):149⁃153. doi: 10.1046/j.1523⁃1747.2000.00061.x.
|
[5] |
Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for stevens⁃johnson syndrome and toxic epidermal necrolysis: a systematic review and meta⁃analysis[J]. JAMA Dermatol, 2017,153(6):514⁃522. doi: 10.1001/jamadermatol.2016.5668.
|
[6] |
Ye LP, Zhang C, Zhu QX. The effect of intravenous immunoglobulin combined with corticosteroid on the progression of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a meta⁃analysis[J]. PLoS One, 2016,11(11):e0167120. doi: 10.1371/journal.pone.0167120.
|
[7] |
Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens⁃Johnson syndrome and toxic epidermal necrolysis[J]. J Invest Dermatol, 2013,133(5):1197⁃1204. doi: 10.1038/jid.2012.510.
|
[8] |
Soares MO, Welton NJ, Harrison DA, et al. Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost⁃effectiveness and value of a further randomised controlled trial[J]. Crit Care, 2014,18(6):649. doi: 10.1186/s13054⁃014⁃0649⁃z.
|
[9] |
Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens⁃Johnson syndrome/toxic epidermal necrolysis in adults 2016[J]. J Plast Reconstr Aesthet Surg, 2016,69(6):e119⁃119e153. doi: 10.1016/j.bjps.2016.01.034.
|
[10] |
Romero⁃Tapia SJ, Cámara⁃Combaluzier HH, Baeza⁃Bacab MA, et al. Use of intravenous immunoglobulin for Stevens⁃Johnson syndrome and toxic epidermal necrolysis in children: report of two cases secondary to anticonvulsants[J]. Allergol Immunopathol (Madr), 2015,43(2):227⁃229. doi: 10.1016/j.aller.2013.12.008.
|
[11] |
Serati Shirazi Z, Inaloo S. Intravenous immunoglobulin in the treatment of lamotrigine⁃ induced toxic epidermal necrolysis[J]. Iran J Allergy Asthma Immunol, 2008,7(4):239⁃241.
|
[12] |
Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens⁃Johnson syndrome and toxic epidermal necrolysis[J]. Nat Med, 2008,14(12):1343⁃1350. doi: 10.1038/nm.1884.
|
[13] |
Kida Y, Kuwano K, Zhang Y, et al. Acholeplasma laidlawii up⁃regulates granulysin gene expression via transcription factor activator protein⁃1 in a human monocytic cell line, THP⁃1[J]. Immunology, 2001,104(3):324⁃332. doi: 10.1046/j.1365⁃2567. 2001.01310.x.
|
[14] |
Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF⁃α antagonist in CTL⁃mediated severe cutaneous adverse reactions[J]. J Clin Invest, 2018,128(3):985⁃996. doi: 10.1172/JCI93349.
|
[15] |
Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis[J]. J Am Acad Dermatol, 2014,71(2):278⁃283. doi: 10.1016/j.jaad.2014.04.044.
|
[16] |
So N, Leavitt E, Aleshin M, et al. The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential[J]. Dermatol Ther, 2018,31(5):e12684. doi: 10.1111/dth.12684.
|
[17] |
陆晓君, 经晶, 施辛, 等. 重组人Ⅱ型肿瘤坏死因子受体⁃抗体融合蛋白治疗中毒性表皮坏死松解症的临床疗效观察[J]. 中华皮肤科杂志, 2020,53(6):428⁃434. doi: 10.35541/cjd. 20200068.
|
[18] |
Famularo G, Di Dona B, Canzona F, et al. Etanercept for toxic epidermal necrolysis[J]. Ann Pharmacother, 2007,41(6):1083⁃1084. doi: 10.1345/aph.1K001.
|
[19] |
Wang F, Gao X, Chen X, et al. Successful treatment of interstitial lung disease related to Stevens⁃Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: a case report and published work review[J]. J Dermatol, 2019,46(11):1035⁃1038. doi: 10.1111/1346⁃8138.15058.
|
[20] |
Bolitho P, Voskoboinik I, Trapani JA, et al. Apoptosis induced by the lymphocyte effector molecule perforin[J]. Curr Opin Immunol, 2007,19(3):339⁃347. doi: 10.1016/j.coi.2007.04.007.
|
[21] |
Trépanier P, Bazin R. Intravenous immunoglobulin (IVIg) inhibits CD8 cytotoxic T⁃cell activation[J]. Blood, 2012,120(13):2769⁃2770. doi: 10.1182/blood⁃2012⁃07⁃445007.
|
[22] |
Trépanier P, Chabot D, Bazin R. Intravenous immunoglobulin modulates the expansion and cytotoxicity of CD8+ T cells[J]. Immunology, 2014,141(2):233⁃241. doi: 10.1111/imm.12189.
|
[23] |
Jacobi C, Claus M, Wildemann B, et al. Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity[J]. Clin Immunol, 2009,133(3):393⁃401. doi: 10.1016/j.clim.2009.09.006.
|